Subscribe to RSS
DOI: 10.5935/2526-8732.20200026
177-Lutecio-DOTATE in the treatment of neuroendocrine rectal tumors with liver metastasis: case report
O Lutecio-177-DOTATE no tratamento do tumor neuroendócrino de reto com metástases hepáticas: relato de caso
Funding The authors received no financial support for the research and authorship of this article.
ABSTRACT
The present report describes a case of a neuroendocrine tumor of the rectum with liver metastasis in a 35-year-old woman. The rectum is the second most common location of gastrointestinal neuroendocrine tumors and is typically diagnosed through a screening colonoscopy finding for non-tumor related symptoms. Surgical treatment is indicated when the disease is localized, but, in most cases, this cancer is diagnosed in advanced stages. When advanced stages or metastasis is present, therapeutic include embolization, somatostatin analogs, interventional radiology and radiometabolic peptide therapy. 177-Lutecio-DOTATATE therapy has a positive impact on the quality of life of patients with inoperable metastatic tumors. The case descried was treated with surgery and later with liver segmentectomies, embolization, and octreotide due to liver tumor recurrence. With the persistence of the metastasis, started treatment with 177-Lutecio-DOTATATE. After the second cycle of administration, had partial remission of the tumor and symptoms.
RESUMO
O presente relato descreve um caso de tumor neuroendócrino do reto com metástase hepática em uma mulher de 35 anos. O reto é o segundo local mais comum de tumores neuroendócrinos gastrointestinais e é tipicamente diagnosticado através de um exame de colonoscopia para detectar sintomas não relacionados ao tumor. O tratamento cirúrgico é indicado quando a doença é localizada, mas, na maioria dos casos, esse câncer é diagnosticado em estágios avançados. Quando estágios avançados ou metástases estão presentes, as terapêuticas incluem embolização, análogos da somatostatina, radiologia intervencionista e terapia com peptídeos radiometabólicos. A terapia com Lutécio-177-DOTATATE tem um impacto positivo na qualidade de vida de pacientes com tumores metastáticos inoperáveis. O caso descrito foi tratado com cirurgia e posteriormente com segmentectomias hepáticas, embolização e octreotida devido à recorrência de tumores hepáticos. Com a persistência das metástases, iniciou-se o tratamento com Lutécio-177-DOTATATE. Após o segundo ciclo de administração, houve remissão parcial do tumor e sintomas.
Disclosures
The authors declared no conflicts of interest with respect to the authorship and publication of this article.
Financial support: none to declare.
Publication History
Received: 01 June 2019
Accepted: 21 July 2019
Article published online:
21 August 2020
© 2022. This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
Mariana Ferrari de Jesus Abdalla, Giselle Cristina dos Santos almeida. 177-Lutecio-DOTATE in the treatment of neuroendocrine rectal tumors with liver metastasis: case report. Brazilian Journal of Oncology 2020; 16: e-20200026.
DOI: 10.5935/2526-8732.20200026
-
REFERENCES
- Oberg K, Knigg U, Kwekkeboom D, Perren A. Neuroendocrine gastro-entero-pancreatic tumors: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; Oct; 23 (Suppl 7): VII124-30s https://doi.org/10.1093/annonc/mds295
- Rodrigues A, Castro-Poças F, Pedroto I. Neuroendocrine rectal tumors: main features and management. J Gastroenterol 2015; Sep/Oct; 22 (05) 213-220 https://doi.org/10.1016/j.jpge.2015.04.008
- Kong G, Grozinsky-Glasberg S, Hofman MS, Akurst T, Meirovitz A, Maimon O. et al Highly favourable outcomes with peptide receptor radionuclide therapy (PRRT) for metastatic rectal neuroendocrine neoplasia (NEN). Eur J Nucl M Mol Imaging 2018; Oct; 46 (03) 718-727 https://doi.org/10.1007/s00259-018-4196-8
- Kim SJ, Pak K, Kwak JJ, Chang S. The efficacy of 177Lulabelled peptide receptor radionuclide therapy in patients with neuroendocrine tumors: a meta-analysis. Eur J Nucl M Mol Imaging 2015; Dec; 42 (13) 1964-1970 https://doi.org/10.1007/s00259-015-3155-x
- Bodei L, Pepe G, Paganelli G. Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues. Eur Rev Med Pharmacol Sci 2010; Apr; 14 (04) 347-351
- Ezziddin S, Attassi M, Yong-Hing CJ, Ahmadazdehfar H, Willinek W, Grünwald F. et al Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-Octreotate. J Nucl Med 2014; Feb; 55 (02) 183-190 https://doi.org/10.2967/jnumed.113.125336
- Skoura E, Michopoulou S, Modmaduvesh M, Panagiotidis E, Al Harbi M, Toumpanakis C. et al The impact of 68Ga-DOTATATE PET/ CT imaging on management of patients with neuroendocrine tumors: experience from a national referral center in the United Kingdom. J Nucl Med 2016; Jan; 57 (01) 34-40 https://doi.org/10.2967/jnumed.115.166017
- Pavel M, Baudin E, Couverlard A, Krenning E, Öberg K, Steinmüller T. et al ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2012; Feb; 95 (02) 157-176 https://doi.org/10.1159/000335597
- Jernman J, Välimäki MJ, Louhimo J, Haglund C, Arola J. The Novel WHO 2010 Classification for gastrointestinal neuroendocrine tumours correlates well with the metastatic potential of rectal neuroendocrine tumors. Neuroendocrinology 2012; 95: 317-324 https://doi.org/10.1159/000333035
- Caplin M, Saudin A, Nillson O, Baum RP, Klose KJ, Kelestimur F. et al ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: colorectal neuroendocrine neoplasms. Neuroendocrinology 2011; Dec; 95: 88-97 https://doi.org/10.1159/000335594
- Pencharz D, Walker M, Yalchin M, Quigley AM, Caplin M, Toumpanakis C. et al Early efficacy of and toxicity from lutetium-177-DOTATATE treatment in patients with progressive metastatic NET. Nucl Med Commun 2017; Jul; 38 (07) 593-600 https://doi.org/10.1097/MNM.0000000000000685
- Forrer F, Uusijärvi H, Storch D, Maecke HR, MuellerBrand J. Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC. J Nucl Med 2009; Aug; 46 (08) 1310-1316
- Wang L, Tang K, Zhang Q, Wen QW, Zhang HH, Zhang H. Somatostatin receptor-based molecular imaging and therapy for neuroendocrine tumors. BioMed Res Int 2013; Sep; 2013 102819 http://dx.doi.org/10.1155/2013/102819
- Silva TN, van Velthuysen MLF, van Eijck CHJ, Teunissen JJ, Hofland J, Herder WW. Successful neoadjuvant peptide receptor radionuclide therapy for an inoperable pancreatic neuroendocrine tumour. Endocrinol Diabetes Metab Case Rep 2018; Apr; 2018 (01) 0015 https://doi.org/10.1530/EDM-18-0015
- Weinstock B, Ward SC, Harpaz N, Warner RRP, Itzkowitz S, Kim MK. Clinical and prognostic features of rectal neuroendocrine tumors. Neuroendocrinology 2013; 98: 180-187 https://doi.org/10.1159/000355612